User:Mr. Ibrahem/Setmelanotide

Setmelanotide, sold under the brand name Imcivree, is a medication used to treat specific genetic causes of obesity. This includes significant pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS). It is used in those at least 6 years old. It is given by injection under the skin.

Common side effects include injection site reactions, increased skin pigmentation, headache, nausea, diarrhea, abdominal pain, and depression. Other side effects may include sexual arousal and thoughts of suicide. Use in not recommended in pregnancy or breast feeding. It is a melanocortin 4 (MC4) receptor agonist.

Setmelanotide was approved for medical use in the United States in 2020 and Europe in 2021. In the United States it costs about 33,000 USD per month as of 2022.